Evonik Industries AG

Evonik Industries AG

11.50
USD
-0.05
(-0.40%)
0.22EPS
58.05P/E
11.36BMarket Cap
Mar 04Next Earn
Evonik Industries AG
OTC:EVKIY
(OTC Markets)

Recent

price

11.50

P/E

ratio

58.05

div

yld

4.89%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
14.28
15.61
14.35
13.64
13.87
14.5
13.67
15.44
14.24
14.07
13.1
16.06
19.85
16.39
16.27
15.1
15.5
Revenue per Share
0.79
1.09
1.25
2.21
0.61
1.06
0.91
0.77
1
2.26
0.5
0.8
0.58
-0.5
0.24
0.28
0.19
Basic EPS, GAAP
1.4
0.46
0.55
-0.03
-0.03
1.13
0.88
0.55
0.87
0.47
0.83
1
0.84
0.86
0.94
0.75
1.08
Free Cash Flow per Basic Share
0.34
0.43
0.46
0.46
0.5
0.5
0.58
0.58
0.58
0.58
0.58
0.58
0.59
0.59
0.59
0.59
0.5
Dividend per Share
5.77
5.72
5.74
7.26
6.9
8.04
8.22
7.98
8.3
9.63
8.6
9.97
11.78
9.57
9.68
8.71
8.62
Book Value per Share
2.03
2.21
2.3
3.99
3.57
4.64
4.66
1.42
1.71
3.34
2.29
3.48
5.65
3.63
3.7
3.23
3.15
Tangible Book Value per Share
931
931
931
931
931
931
931
931
931
931
931
931
931
931
931
931
938
Basic Weighted Avg Shares
13,300
14,540
13,365
12,708
12,917
13,507
12,732
14,383
13,267
13,108
12,199
14,955
18,488
15,267
15,157
14,069
14,548
Sales/Revenue/Turnover
10.07
12.95
14.25
9.55
8.95
12.13
10.68
8.84
8.5
8.94
6.89
8.22
6.8
-0.65
4.22
4.56
3.55
Operating Margin (%)
799
785
745
638
656
764
747
923
787
984
1,018
1,073
1,568
1,841
1,117
1,203
1,207
Depreciation Expense
734
1,011
1,165
2,054
568
991
844
713
932
2,106
465
746
540
-465
222
265
174
Net Income, GAAP
17.95
29.23
29.11
27.69
29.93
29.29
32.21
28.57
20.81
18.87
26.46
29.12
39.98
- -
44.7
34.36
33.33
Effective Tax Rate (%)
5.52
6.95
8.72
16.16
4.4
7.34
6.63
4.96
7.02
16.07
3.81
4.99
2.92
-3.05
1.46
1.88
1.2
Profit Margin (%)
3,357
2,469
1,464
2,457
2,512
3,609
5,607
2,143
2,239
3,054
2,037
2,118
3,017
1,856
1,449
1,639
1,249
Working Capital
2,867
2,745
1,464
625
632
1,359
3,230
3,694
3,684
3,701
3,541
3,478
4,041
3,312
2,944
3,295
- -
LT Debt
5,969
5,421
5,460
6,836
6,522
7,576
7,745
7,519
7,825
9,060
8,099
9,372
11,056
8,986
9,100
8,174
8,090
Total Equity
10.21
13.13
13.82
8.39
8.81
13.93
8.63
7.98
6.8
7
4.7
6.56
3.95
- -
2.45
3.04
- -
Return on Invested Capital (%)
11.27
14.89
16.65
27.36
9.55
13.94
9.67
7.64
9.21
17.97
4.53
6.54
4.23
- -
2.46
3.18
- -
Return on Capital (%)
14.53
18.89
21.82
33.93
8.62
14.24
11.14
9.45
12.3
25.22
5.48
8.62
5.33
-4.68
2.48
3.09
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
931
931
931
Market Capitalization
7,905
7,322
10,026

Working Capital

EUR

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
5,431
5,658
5,890
Cash, Cash Equivalents & STI
801
587
762
Accounts Receivable, Net
1,728
1,885
1,864
Inventories
2,429
2,682
2,792
Total Current Liabilities
3,599
3,782
4,641
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.46%
1.21%
-10.18%
Free Cash Flow
2.37%
-0.87%
-20.39%
Net Income, GAAP
-23.32%
-56.33%
19.37%
Sales/Revenue/Turnover
1.22%
4.18%
-7.18%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,796
3,930
3,832
3,599
15,157
2025
3,777
3,499
- -
3,403
14,069
2026
3,427
3,893
3,825
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
-0.01
0.24
-0.16
0.24
2025
0.25
0.13
- -
0.02
0.28
2026
0.14
0.09
-0.06
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.55
- -
- -
0.59
2025
- -
0.59
- -
- -
0.59
2026
- -
0.5
- -
- -
- -
Business
Evonik Industries AG is a Germany-based global specialty chemicals company headquartered in Essen, North Rhine-Westphalia. Founded in 1919, the company operates in more than 100 countries and employs approximately 32,000 people. Its core business focuses on the manufacture and sale of specialty chemical products through several key segments: Specialty Additives, Nutrition & Care, Smart Materials, Performance Materials, and Technology & Infrastructure. The Specialty Additives segment offers additives and crosslinkers for growth markets such as coatings, mobility, and consumer goods. Nutrition & Care provides sustainable solutions to improve health and quality of life, including products for personal care, medical applications, drug delivery systems, and animal nutrition. Smart Materials includes innovative materials aimed at resource efficiency and substitution of conventional materials. Performance Materials supplies technology platforms for producing high-volume intermediates serving mobility, plastics, and rubber industries. Technology & Infrastructure encompasses site services and technical operations critical to chemical production facilities. Recent major changes at Evonik include a significant strategic realignment announced in 2024, where the company is reorganizing from three business lines into two growth-oriented divisions: Customized Solutions and Advanced Technologies, effective April 1, 2025. Both new divisions are expected to generate annual sales of approximately €6 billion each. The company is focusing its Health Care and Coating & Adhesive Resins businesses on their core growth areas, including lipids for mRNA and gene therapy, drug delivery systems, and cell culture ingredients, while divesting or discontinuing less core operations. Additionally, Evonik completed the sale of its Superabsorbers business in early 2024, which generated around €892 million in sales. These changes reflect Evonik’s broader industry response to structural change by concentrating resources on its strongest and highest growth potential businesses to accelerate investment and enhance competitiveness. Evonik serves diverse industries with its specialty chemicals and related services, including automotive, coatings, agriculture, consumer goods, pharmaceuticals, and energy sectors. The company’s agriculture segment offers specialty chemicals such as active oxygens, catalysts, and formulations that support sustainable farming practices and crop protection. Its pharmaceutical contract development and manufacturing organization (CDMO) business provides small molecule active pharmaceutical ingredients (APIs), drug delivery devices, and various custom manufacturing services. Evonik emphasizes sustainability, recently achieving ISCC PLUS certification for specialty chemical production, underscoring its commitment to environmentally responsible manufacturing. Evonik Industries AG is publicly listed under the ticker EVK.DE and is predominantly owned by the RAG Foundation. It generated sales of €15.2 billion and adjusted EBITDA of €2.1 billion in 2024. The company’s strategic focus on specialty chemicals with high value-added solutions, combined with its global reach and recent restructuring, positions it as a leading innovator in the global chemical industry. This description reflects Evonik’s current business structure, product portfolio, and major strategic initiatives as of late 2025.

Company News

  • Evonik Industries AG (EVKIY) Q3 2026 Earnings Call Transcript

  • Germany's RAG Foundation could sell entire Evonik stake

  • Chemicals Giant BASF Moves for Rival Evonik

  • Evonik Industries AG (EVKIY) Q2 2026 Earnings Call Transcript

  • Evonik Industries AG (EVKIY) Shareholder/Analyst Call Transcript

  • Evonik Industries AG (EVKIY) Q1 2026 Earnings Call Transcript

  • Evonik Industries (OTCMKTS:EVKIF) Shares Up 7.5% – What’s Next?

  • Evonik Industries AG (EVKIY) Q4 2025 Earnings Call Transcript

  • Evonik Industries AG (EVKIY) Q3 2025 Earnings Call Transcript

  • Evonik: Revised Outlook Necessitates A Q3 2025 Update

  • Look Beyond The Volatility In Evonik Industries

  • Evonik Industries AG (EVKIF) Q2 2025 Earnings Call Transcript

  • Evonik Industries AG (EVKIF) Q1 2025 Earnings Call Transcript

  • Evonik: Decent Rate Of Return, Upside Confirmed

  • Evonik Industries AG (EVKIF) Q4 2024 Earnings Call Transcript

  • Evonik: A Good Company, Upside Less Clear Than Before

  • Evonik Industries AG (EVKIF) Q3 2024 Earnings Call Transcript

  • AI-Driven Market Transformation, Emission Control Catalysts Market to Grow by USD 4.01 Billion (2024-2028) Boosted by Global Automotive Sector - Technavio Report

  • Squalene Market to Grow by USD 62.9 Million from 2024-2028, Driven by Rising Adoption of UVA/UVB Filters in Sunscreens, Report Powered by AI - Technavio

  • Evonik - I Continue To Be Long Here